Acute S100B in serum is associated with cognitive symptoms and memory performance 4 months after paediatric mild traumatic brain injury

Studer, Martina; Goeggel Simonetti, Barbara; Heinks Maldonado, Theda; Steinlin, Maja; Leichtle, Alexander Benedikt; Berger, Steffen Michael; Joeris, Alexander (2015). Acute S100B in serum is associated with cognitive symptoms and memory performance 4 months after paediatric mild traumatic brain injury. Brain injury, 29(13-14), pp. 1667-1673. Informa Healthcare 10.3109/02699052.2015.1075250

[img]
Preview
Text
Acute S100B in Serum is associated with cognitive symptoms and memory performance four.pdf - Accepted Version
Available under License Publisher holds Copyright.

Download (7MB) | Preview

OBJECTIVE This study explored whether acute serum marker S100B is related with post-concussive symptoms (PCS) and neuropsychological performance 4 months after paediatric mild traumatic brain injury (mTBI). RESEARCH DESIGN AND METHODS This prospective short-term longitudinal study investigated children (aged 6-16 years) with mTBI (n = 36, 16 males) and children with orthopaedic injuries (OI, n = 27, 18 males) as a control group. S100B in serum was measured during the acute phase and was correlated with parent-rated PCS and neuropsychological performance 4 months after the injury. MAIN OUTCOMES AND RESULTS The results revealed no between-group difference regarding acute S100B serum concentration. In children after mTBI, group-specific significant Spearman correlations were found between S100B and post-acute cognitive PCS (r = 0.54, p = 0.001) as well as S100B and verbal memory performance (r = -0.47, p = 0.006). In children after OI, there were insignificant positive relations between S100B and post-acute somatic PCS. In addition, insignificant positive correlations were found between neuropsychological outcome and S100B in children after OI. CONCLUSIONS S100B was not specific for mild brain injuries and may also be elevated after OI. The group-specific association between S100B and ongoing cognitive PCS in children after mTBI should motivate to examine further the role of S100B as a diagnostic biomarker in paediatric mTBI.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Institute of Clinical Chemistry
04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Paediatric Medicine
04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Paediatric Surgery

UniBE Contributor:

Studer, Martina; Heinks Maldonado, Theda; Steinlin, Maja; Leichtle, Alexander Benedikt; Berger, Steffen Michael and Joeris, Alexander

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0269-9052

Publisher:

Informa Healthcare

Language:

English

Submitter:

Christoph Steffen

Date Deposited:

11 Feb 2016 14:19

Last Modified:

27 Oct 2016 02:30

Publisher DOI:

10.3109/02699052.2015.1075250

PubMed ID:

26502808

Uncontrolled Keywords:

Biomarker S100B serum; neuropsychological outcome; paediatric mild traumatic brain injury; post-concussive symptoms

BORIS DOI:

10.7892/boris.75067

URI:

https://boris.unibe.ch/id/eprint/75067

Actions (login required)

Edit item Edit item
Provide Feedback